Literature DB >> 11745832

Adverse effects of prenatal methimazole exposure.

E Di Gianantonio1, C Schaefer, P P Mastroiacovo, M P Cournot, F Benedicenti, M Reuvers, B Occupati, E Robert, B Bellemin, A Addis, J Arnon, M Clementi.   

Abstract

BACKGROUND: A specific phenotype of methimazole (MMI) induced malformations has recently been postulated. MMI embryopathy is characterized by minor dysmorphic features, choanal atresia and/or esophageal atresia, growth retardation, and developmental delay.
METHODS: We prospectively studied the outcome of pregnancy in 241 women counseled by 10 Teratology Information Services (TIS) of the European Network of Teratology Information Services (ENTIS) because of MMI exposure, and compared them with those of 1,089 pregnant women referred to TIS because of exposure to nonteratogenic drugs (control group). Information was obtained by mail or telephone interview.
RESULTS: There was no increase in the general rate of major anomalies or of spontaneous or induced abortions in the MMI-exposed group in comparison with the control group. Two newborns were affected with one of the major malformations that are part of the postulated embryopathy.
CONCLUSIONS: The results of this study indicate that choanal as well as esophageal atresia may have a higher incidence than expected in fetuses exposed to MMI between 3 and 7 gestational weeks. Until further data are available, thyrotoxicosis should be treated with propylthiouracil, as it is apparently safer for use during the fertile period. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745832     DOI: 10.1002/tera.1072

Source DB:  PubMed          Journal:  Teratology        ISSN: 0040-3709


  23 in total

1.  Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008.

Authors:  Ana B Emiliano; Laura Governale; Mary Parks; David S Cooper
Journal:  J Clin Endocrinol Metab       Date:  2010-03-24       Impact factor: 5.958

Review 2.  [Thyroid and pregnancy].

Authors:  Johanna Mayr; Susanne Kohlfürst; Hans-Jürgen Gallowitsch; Peter Lind; Peter Mikosch
Journal:  Wien Med Wochenschr       Date:  2010-04

Review 3.  Therapeutic drug monitoring of antithyroid drugs in pregnancy: the knowledge gaps.

Authors:  Gideon Koren; Offie Soldin
Journal:  Ther Drug Monit       Date:  2006-02       Impact factor: 3.681

4.  Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy.

Authors:  E Gianetti; L Russo; F Orlandi; L Chiovato; M Giusti; S Benvenga; M Moleti; F Vermiglio; P E Macchia; M Vitale; C Regalbuto; M Centanni; E Martino; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2015-04-04       Impact factor: 4.256

Review 5.  Side effects of anti-thyroid drugs and their impact on the choice of treatment for thyrotoxicosis in pregnancy.

Authors:  Peter N Taylor; Bijay Vaidya
Journal:  Eur Thyroid J       Date:  2012-09-24

6.  A Case of Propylthiouracil-Induced Hepatitis during Pregnancy.

Authors:  Peter Taylor; Sandip Bhatt; Ravi Gouni; Jonathan Quinlan; Tony Robinson
Journal:  Eur Thyroid J       Date:  2012-02-29

7.  Gestational thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated healthcare delivery system.

Authors:  Joan C Lo; Scott A Rivkees; Malini Chandra; Joel R Gonzalez; James J Korelitz; Michael W Kuzniewicz
Journal:  Thyroid       Date:  2015-04-14       Impact factor: 6.568

Review 8.  Hyperthyroidism during pregnancy.

Authors:  Miho Inoue; Naoko Arata; Gideon Koren; Shinya Ito
Journal:  Can Fam Physician       Date:  2009-07       Impact factor: 3.275

Review 9.  Etiology of esophageal atresia and tracheoesophageal fistula: "mind the gap".

Authors:  Elisabeth M de Jong; Janine F Felix; Annelies de Klein; Dick Tibboel
Journal:  Curr Gastroenterol Rep       Date:  2010-06

10.  Maternal hyperthyroidism increases the prevalence of foregut atresias in fetal rats exposed to adriamycin.

Authors:  Ana Catarina Fragoso; Leopoldo Martinez; José Estevão-Costa; Juan A Tovar
Journal:  Pediatr Surg Int       Date:  2014-02       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.